Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 32853585)

Published in Lancet Haematol on September 01, 2020

Authors

Catherine S Diefenbach1, Fangxin Hong2, Richard F Ambinder3, Jonathon B Cohen4, Michael J Robertson5, Kevin A David6, Ranjana H Advani7, Timothy S Fenske8, Stefan K Barta9, Neil D Palmisiano10, Jakub Svoboda11, David S Morgan12, Reem Karmali13, Elad Sharon14, Howard Streicher14, Brad S Kahl15, Stephen M Ansell16

Author Affiliations

1: Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Electronic address: catherine.diefenbach@nyulangone.org.
2: Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Biostatistics Center, Dana Farber Cancer Institute, Boston, MA, USA.
3: Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
4: Winship Cancer Institute, Emory University, Atlanta, GA, USA.
5: School of Medicine, Indiana University, Bloomington, IN, USA.
6: Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Jersey, NJ, USA.
7: Oncology Division, Stanford Cancer Institute, Stanford, CA, USA.
8: Division of Hematology and Oncology, Froedtert and the Medical College of Wisconsin, Wauwatosa, WI, USA.
9: Divison of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
10: Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
11: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
12: Vanderbilt University Medical Center, Nashville, TN, USA.
13: Robert H Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, USA.
14: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethseda, MD, USA.
15: School of Medicine, Washington University, St Louis, MO, USA.
16: Division of Hematology, Mayo Clinic, Rochester MN, USA.

Associated clinical trials:

Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01896999